[go: up one dir, main page]

FR13C0060I2 - Omega-carboxyaryldiphenyluree fluoro-subtituee pour le traitement et la prevention de maladies et d'etats pathologiques - Google Patents

Omega-carboxyaryldiphenyluree fluoro-subtituee pour le traitement et la prevention de maladies et d'etats pathologiques

Info

Publication number
FR13C0060I2
FR13C0060I2 FR13C0060C FR13C0060C FR13C0060I2 FR 13C0060 I2 FR13C0060 I2 FR 13C0060I2 FR 13C0060 C FR13C0060 C FR 13C0060C FR 13C0060 C FR13C0060 C FR 13C0060C FR 13C0060 I2 FR13C0060 I2 FR 13C0060I2
Authority
FR
France
Prior art keywords
carboxyaryldiphenylurea
fluoro
diseases
prevention
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR13C0060C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Healthcare LLC
Original Assignee
Bayer Healthcare LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34107784&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR13C0060(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare LLC filed Critical Bayer Healthcare LLC
Publication of FR13C0060I1 publication Critical patent/FR13C0060I1/fr
Application granted granted Critical
Publication of FR13C0060I2 publication Critical patent/FR13C0060I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
FR13C0060C 2003-07-23 2013-11-08 Omega-carboxyaryldiphenyluree fluoro-subtituee pour le traitement et la prevention de maladies et d'etats pathologiques Active FR13C0060I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48910203P 2003-07-23 2003-07-23
US54032604P 2004-02-02 2004-02-02
PCT/US2004/023500 WO2005009961A2 (fr) 2003-07-23 2004-07-22 Omega-carboxyaryldiphenyluree fluoro-subtituee pour le traitement et la prevention de maladies et d'etats pathologiques

Publications (2)

Publication Number Publication Date
FR13C0060I1 FR13C0060I1 (fr) 2013-12-13
FR13C0060I2 true FR13C0060I2 (fr) 2014-04-11

Family

ID=34107784

Family Applications (1)

Application Number Title Priority Date Filing Date
FR13C0060C Active FR13C0060I2 (fr) 2003-07-23 2013-11-08 Omega-carboxyaryldiphenyluree fluoro-subtituee pour le traitement et la prevention de maladies et d'etats pathologiques

Country Status (36)

Country Link
US (3) US8637553B2 (fr)
EP (1) EP1663978B1 (fr)
JP (2) JP4777887B2 (fr)
KR (1) KR101139557B1 (fr)
CN (2) CN1856469B (fr)
AR (3) AR048741A1 (fr)
AU (2) AU2004259760B9 (fr)
BE (1) BE2013C067I2 (fr)
BR (2) BRPI0412219B8 (fr)
CA (1) CA2532865C (fr)
CL (1) CL2004001834A1 (fr)
CR (1) CR10193A (fr)
CY (2) CY1107094T1 (fr)
DE (1) DE602004010407T2 (fr)
DK (1) DK1663978T3 (fr)
EA (1) EA010485B1 (fr)
EC (1) ECSP066302A (fr)
ES (1) ES2297490T3 (fr)
FR (1) FR13C0060I2 (fr)
HR (1) HRP20060073B1 (fr)
HU (1) HUS1300073I1 (fr)
IL (1) IL173256A (fr)
LU (1) LU92300I2 (fr)
MA (1) MA27946A1 (fr)
ME (1) ME00294B (fr)
MY (1) MY142799A (fr)
NO (1) NO335323B1 (fr)
NZ (2) NZ544920A (fr)
PL (1) PL1663978T3 (fr)
PT (1) PT1663978E (fr)
RS (1) RS52625B (fr)
SI (1) SI1663978T1 (fr)
TN (1) TNSN06020A1 (fr)
TW (1) TWI341201B (fr)
UA (1) UA84156C2 (fr)
WO (1) WO2005009961A2 (fr)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE538794T1 (de) 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
US20080108672A1 (en) * 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
SI1580188T1 (sl) 2002-02-11 2012-02-29 Bayer Healthcare Llc Aril sečnine kot kinazni inhibitorji
SI1478358T1 (sl) 2002-02-11 2013-09-30 Bayer Healthcare Llc Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
NZ562412A (en) * 2003-02-21 2009-02-28 Resmed Ltd Nasal assembly for pillow mask
US7557129B2 (en) * 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
EP1626714B1 (fr) * 2003-05-20 2007-07-04 Bayer Pharmaceuticals Corporation Urees de diaryle pour des maladies mediees par le recepteur du facteur de croissance derive des plaquettes
EP1663978B1 (fr) 2003-07-23 2007-11-28 Bayer Pharmaceuticals Corporation Omega-carboxyaryldiphenyluree fluoro-subtituee pour le traitement et la prevention de maladies et d'etats pathologiques
RU2006122853A (ru) * 2003-11-28 2008-01-10 Новартис АГ (CH) Производные диарилмочевины для лечения заболеваний, зависимых от протеинкиназы
WO2005110994A2 (fr) 2004-04-30 2005-11-24 Bayer Pharmaceuticals Corporation Derives de pyrazolyl uree substitues utiles dans le traitement du cancer
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
AU2011244932B9 (en) * 2004-08-27 2014-06-12 Bayer Pharmaceuticals Corporation New pharmaceutical compositions comprising 4-(4-(3-(4-chloro-3-trifluoromethyl-phenyl)-ureido)-3-fluoro-phenoxy)-pyridine-2-carboxylic acid for the treatment of hyper-proliferative disorders
BRPI0515946A (pt) * 2004-09-29 2008-08-12 Bayer Healthcare Ag sal de tosilato, sua preparação e uso, bem como composição farmacêutica compreendendo o mesmo
CN113952459B (zh) 2005-02-03 2025-02-11 综合医院公司 治疗吉非替尼耐药性癌症的方法
CA2601955C (fr) 2005-03-07 2012-07-10 Bayer Healthcare Ag Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancer
US20060216288A1 (en) * 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer
US20090305236A1 (en) * 2005-05-11 2009-12-10 Genetic Technologies Limited Methods of enriching fetal cells
KR20080012902A (ko) * 2005-05-27 2008-02-12 바이엘 헬스케어 아게 질병을 치료하기 위한 디아릴 우레아를 포함하는 병용요법
RU2007148266A (ru) * 2005-05-27 2009-07-10 Байер ХельсКер АГ (DE) Комбинированная терапия с использованием соединения диарилмочевины и ингибиторов pi3, akt-киназы или mtor (рапамицины) для лечения рака
CN103110948A (zh) 2005-11-04 2013-05-22 惠氏公司 mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
RU2431484C2 (ru) * 2005-11-10 2011-10-20 Байер Шеринг Фарма Акциенгезельшафт Диарилмочевина для лечения легочной гипертензии
WO2007054303A2 (fr) * 2005-11-10 2007-05-18 Bayer Healthcare Ag Diaryle-uree servant a traiter une neuropathie diabetique
AU2006312714A1 (en) * 2005-11-10 2007-05-18 Bayer Schering Pharma Aktiengesellschaft Diaryl urea for treating pulmonary hypertension
US20100129321A1 (en) * 2005-12-15 2010-05-27 Bayer Healthcare Llc Diaryl urea for treating virus infections
EP1962842A1 (fr) * 2005-12-15 2008-09-03 Bayer HealthCare AG Diaryle-urees pour le traitement de maladies inflammatoires de la peau, l'oeil et/ou l'oreille
WO2007068382A1 (fr) * 2005-12-15 2007-06-21 Bayer Healthcare Ag Diaryle-uree pour le traitement de maladies inflammatoires de la peau, l'oeil et/ou l'oreille
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
WO2007100880A1 (fr) * 2006-02-28 2007-09-07 Amgen Inc. Cinnoline et derives de quinoxaline en tant qu'inhibiteurs de phosphodiesterase 10
CN101058561B (zh) * 2006-04-19 2011-01-26 苏州爱斯鹏药物研发有限责任公司 用于抑制蛋白激酶的二苯脲衍生物及其组合物和用途
WO2007145704A2 (fr) 2006-04-24 2007-12-21 Gloucester Pharmaceuticals Thérapie de combinaison de gemcitabine
WO2007139930A2 (fr) * 2006-05-26 2007-12-06 Bayer Healthcare Llc Associations de médicaments comportant des urées de diaryle substituées pour le traitement du cancer
WO2007146730A2 (fr) 2006-06-08 2007-12-21 Gloucester Pharmaceuticals Thérapie à base d'inhibiteurs de désacétylase (dac)
CL2007001829A1 (es) * 2006-06-23 2008-01-25 Smithkline Beecham Corp P-toluensulfonato de n-[4-cloro-2-hidroxi-3-(piperazina-1-sulfonil)fenil]-n-(2-cloro-3-fluorofenil)urea;procedimiento de preparacion;composicion farmaceutica;combinacion farmaceutica;y uso en el tratamiento de una enfermedad mediada por la quiimioquina il-8, tales como asma y epoc.
US20080064729A1 (en) * 2006-09-07 2008-03-13 Millennium Pharmaceuticals, Inc. Phenethylamide derivatives with kinase inhibitory activity
WO2008044688A1 (fr) * 2006-10-11 2008-04-17 Daiichi Sankyo Company, Limited Dérivé de l'urée
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
CA2668748A1 (fr) * 2006-11-09 2008-05-15 Bayer Schering Pharma Aktiengesellschaft Polymorphe iii de 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide
EP2089363A1 (fr) * 2006-11-14 2009-08-19 Bayer Schering Pharma Aktiengesellschaft Polymorphe ii de 4-[4-({[4-chloro-3-(trifluorométhyl)phényl]carbamoyl}amino)-3-fluorophénoxy]-n-méthylpyridine-2-carboxamide
CN107090482A (zh) 2006-12-29 2017-08-25 细胞基因公司 制备Romidepsin
EP2117598A2 (fr) * 2007-01-10 2009-11-18 Novartis AG Formulations d'inhibiteurs de la déacétylase
US8680124B2 (en) 2007-01-19 2014-03-25 Bayer Healthcare Llc Treatment of cancers with acquired resistance to kit inhibitors
WO2008089388A2 (fr) * 2007-01-19 2008-07-24 Bayer Healthcare Llc Traitement de cancers présentant une résistance à des agents chimiothérapeutiques
US20080234332A1 (en) * 2007-03-20 2008-09-25 Xiong Cai Raf kinase inhibitors containing a zinc binding moiety
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
WO2008120004A1 (fr) * 2007-04-02 2008-10-09 Astrazeneca Ab Combinaison d'un inhibiteur de mek et d'un inhibiteur de b-raf pour le traitement du cancer
EP2182941B1 (fr) 2007-07-25 2018-02-28 Eisai R&D Management Co., Ltd. Inhibiteurs multikinase à utiliser dans le traitement du cancer
WO2009021150A2 (fr) 2007-08-08 2009-02-12 California Pacific Medical Center Le récepteur du facteur de croissance dérivés des plaquettes tolère l'infectiosité du cytomégalovirus
CL2008002786A1 (es) * 2007-09-20 2009-05-15 Novartis Ag Torta farmceuticamente aceptable, formada por liofilizacion, que comprende: n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il]-etil]-amino]-metil]-fenil]-2e-2-propenamida o una sal, un regulador de ph seleciondo de lactato o acidop lactico, fodfato o acido fosforico o una combinacion y un agente de volumen; proceso de elaboracion.
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
WO2009058908A2 (fr) * 2007-10-29 2009-05-07 Eisai R & D Management Co., Ltd. Procédés de pronostic de l'aptitude à traiter le cancer d'un composé analogue de la zéaralénone
CN101220024A (zh) * 2007-12-11 2008-07-16 杜晓敏 一组抑制激酶的抗癌化合物
WO2009132397A1 (fr) * 2008-05-01 2009-11-05 University Of South Australia Procédés et agents pour la modulation du taux et/ou de l'activité de la protéine hif-2 alpha
CN102641270A (zh) 2008-06-17 2012-08-22 惠氏有限责任公司 含有hki-272和长春瑞滨的抗肿瘤组合
MX2010014441A (es) * 2008-06-25 2011-01-21 Bayer Schering Pharma Ag Diaril ureas para tratar la insuficiencia cardiaca.
US20110178137A1 (en) * 2008-06-25 2011-07-21 Bayer Schering Pharma Aktiengesellschaft Diaryl urea for treating heart failure
US9410956B1 (en) * 2008-08-01 2016-08-09 University Of South Florida Micro-RNA profiling in ovarian cancer
HUE032958T2 (hu) 2008-08-04 2017-11-28 Wyeth Llc 4-Anilino-3-ciano-kinolinok és capecitabin antineoplasztikus kombinációi
EP2156834A1 (fr) * 2008-08-08 2010-02-24 S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. Compositions pharmaceutiques ophtalmiques comprenant du Sorafenib pour le traitement de pathologies néoangiogéniques de l'ýil
WO2010019701A2 (fr) * 2008-08-14 2010-02-18 Concert Pharmaceuticals, Inc. Dérivés de diaryl urée
CN102516154B (zh) * 2008-09-19 2015-03-18 苏州泽璟生物制药有限公司 氘代的ω-二苯基脲及衍生物以及包含该化合物的药物组合物
CN103254126A (zh) * 2008-09-19 2013-08-21 苏州泽璟生物制药有限公司 氘代的ω-二苯基脲及衍生物以及包含该化合物的药物组合物
WO2010108503A1 (fr) 2009-03-24 2010-09-30 Life & Brain Gmbh Promotion de l'intégration neuronale dans des greffons de cellules souches neurales
LT3000467T (lt) 2009-04-06 2023-04-11 Wyeth Llc Krūties vėžio gydymo schema naudojant neratinibą
US8410082B2 (en) 2009-05-22 2013-04-02 Concert Pharmaceuticals, Inc. Fluorinated diaryl urea derivatives
CN102190616B (zh) * 2010-03-18 2015-07-29 苏州泽璟生物制药有限公司 一种氘代的ω-二苯基脲的合成及生产的方法和工艺
AR081060A1 (es) * 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
AU2015201426B2 (en) * 2010-04-15 2016-07-07 Bayer Healthcare Llc Process for the preparation of 4- {4-[({[4 -chloro-3 -(trifluoromethyl)-phenyl]amino} carbonyl)amino]-3-fluorophenoxy}-N-methylpyridine-2-carboxamide, its salts and monohydrate
WO2011130728A1 (fr) * 2010-04-17 2011-10-20 Bayer Healthcare Llc Métabolites synthétiques d'oméga-carboxyaryldiphénylurées fluorosubstituées pour le traitement et la prévention de maladies et d'états
WO2011146725A1 (fr) 2010-05-19 2011-11-24 Bayer Healthcare Llc Biomarqueurs pour un inhibiteur à multiples kinases
CN103108648A (zh) 2010-07-12 2013-05-15 细胞基因公司 罗米地辛固体形式及其用途
CA2805874A1 (fr) * 2010-07-19 2012-01-26 Bayer Healthcare Llc Associations medicamenteuses contenant une omega-carboxyaryl diphenyluree fluorosubstituee utilisees pour le traitement et la prevention de maladies et d'affections
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
US20140057908A1 (en) 2010-09-27 2014-02-27 Exelixis, Inc. Method of Treating Cancer
EP2621486A1 (fr) 2010-10-01 2013-08-07 Bayer Intellectual Property GmbH Combinaisons contenant du n-(2-arylamino)arylsulfonamide substitué
WO2012118978A1 (fr) * 2011-03-03 2012-09-07 The Regents Of The University Of Colorado, A Body Corporate Procédés pour traiter des cancers positifs aux oncovirus
ES2699532T3 (es) 2011-03-23 2019-02-11 Univ California Métodos y composiciones para mejorar la terapia antiangiogénica con anti-integrinas
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
WO2012162025A1 (fr) * 2011-05-20 2012-11-29 President And Fellows Of Harvard College Procédés de sélection de patients cancéreux pour traitement par des composés de n,n'-diarylurée et de n,n'-diarlythiourée
US20140296301A1 (en) * 2011-06-28 2014-10-02 Bayer Pharma Aktiengesellschaft Topical ophthalmological pharmaceutical composition containing regoragenib
EP2543372A1 (fr) * 2011-07-08 2013-01-09 Helmholtz-Zentrum für Infektionsforschung GmbH Médicament pour le traitement du cancer du foie
EP2729146B1 (fr) 2011-07-08 2017-03-08 Helmholtz-Zentrum für Infektionsforschung GmbH Médicament pour le traitement du cancer du foie
KR101374530B1 (ko) * 2011-07-14 2014-03-14 연세대학교 원주산학협력단 디에틸스틸베스트롤을 함유하는 심혈관 질환의 예방 또는 치료용 조성물
KR101909433B1 (ko) * 2011-12-02 2018-10-18 고쿠리츠다이가쿠호우진 야마구치 다이가쿠 키나제 저해제의 부작용 저감제
CN103169720B (zh) * 2011-12-21 2016-12-07 张雅珍 蒽环类抗生素及其可药用盐在治疗视网膜静脉阻塞中的用途
BRPI1107182B1 (pt) * 2011-12-29 2022-03-08 Fundação De Amparo À Pesquisa Do Estado De Minas Gerais - Fapemig Composições farmacêuticas contendo ang-(1-7) ou outro agonista do receptor mas em combinação com inibidores de pi3k/akt para tratamento terapêutico anticâncer
WO2013178581A1 (fr) 2012-05-31 2013-12-05 Bayer Pharma Aktiengesellschaft Biomarqueurs pour la détermination de la réponse efficace de traitements de patients atteints d'un carcinome hépatocellulaire (hcc)
WO2013188279A1 (fr) * 2012-06-12 2013-12-19 Bayer Healthcare Llc Composition pharmaceutique ophtalmique topique contenant du cediranib
KR101386697B1 (ko) * 2012-06-18 2014-04-18 아주대학교산학협력단 이매티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물
AR092439A1 (es) 2012-09-06 2015-04-22 Bayer Healthcare Llc Composicion farmaceutica recubierta que contiene regorafenib
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
MX357035B (es) * 2012-09-25 2018-06-25 Bayer Pharma AG Combinacion de regorafenib y acido acetilsalicilico para el tratamiento del cancer.
PE20150886A1 (es) 2012-10-15 2015-06-04 Epizyme Inc Compuestos de benceno sustituidos
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
UY35183A (es) 2012-12-21 2014-07-31 Bayer Healthcare Llc Composición farmacéutica oftalmológica tópica que contiene regorafenib
CN104250227A (zh) * 2013-06-29 2014-12-31 广东东阳光药业有限公司 瑞戈非尼新晶型及其制备方法
WO2015006753A2 (fr) * 2013-07-12 2015-01-15 The Regents Of The University Of California Thérapies pour des maladies causées par des parasites portés par des arthropodes
WO2015011659A1 (fr) * 2013-07-24 2015-01-29 Dr. Reddys Laboratories Limited Formes polymorphes cristallines du régorafénib et méthodes de préparation de la forme polymorphe i du régorafénib
WO2015035531A1 (fr) * 2013-09-12 2015-03-19 杭州普晒医药科技有限公司 Forme cristalline du régorafénib, son procédé de préparation et son utilisation
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
CN103923000A (zh) * 2014-01-29 2014-07-16 苏州晶云药物科技有限公司 几种新晶型及其制备方法
CN103923001B (zh) * 2014-04-30 2016-02-10 药源药物化学（上海）有限公司 瑞戈非尼盐及其晶型、制备方法
WO2016005874A1 (fr) * 2014-07-09 2016-01-14 Shilpa Medicare Limited Procédé pour la préparation du régorafénib et ses formes cristallines
WO2016038590A1 (fr) 2014-09-12 2016-03-17 Mylan Laboratories Ltd Procédé de préparation de la forme cristalline i du régorafénib
WO2016051422A2 (fr) * 2014-09-29 2016-04-07 Msn Laboratories Private Limited Procédé permettant de préparer le 4-[4-({[4-chloro-3-(trifluorométhyl)phényl]carbamoyl}amino)-3-fluorophénoxy]-n-méthylpyridine-2-carboxamide et ses formes polymorphes
CN105566215B (zh) * 2014-10-17 2018-02-16 沈阳药科大学 一种瑞戈非尼的制备方法
CN105777625B (zh) * 2014-12-24 2020-05-22 浙江海正药业股份有限公司 一种制备4-（4-氨基-3-氟苯氧基）-n-甲基吡啶-2-甲酰胺的方法
CN104586808B (zh) * 2014-12-27 2017-08-18 北京元延医药科技股份有限公司 抗肿瘤药物组合物
CN104910067A (zh) * 2015-03-05 2015-09-16 南京工业大学 一锅法合成瑞戈非尼的方法
CN105218440A (zh) * 2015-09-07 2016-01-06 河南中医学院 一种高纯瑞戈非尼的制备方法
CN105330600B (zh) * 2015-11-30 2018-05-22 山东罗欣药业集团股份有限公司 一种瑞戈菲尼的制备方法
SG11201806116SA (en) * 2016-01-18 2018-08-30 Natco Pharma Ltd An improved process for the preparation of regorafenib
US10435409B2 (en) 2016-02-04 2019-10-08 Shilpa Medicare Limited Process for the preparation of ibrutinib
US10456413B2 (en) * 2016-03-02 2019-10-29 Medivir Aktiebolag Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine
CA3034332A1 (fr) 2016-08-17 2018-02-22 Ichan School Of Medicine At Mount Sinai Composes inhibiteurs de kinase, compositions et methodes de traitement du cancer
HRP20241188T1 (hr) 2017-04-18 2024-12-06 Eli Lilly And Company Fenil-2-hidroksi-acetilamino-2-metil-fenil spojevi
AU2018276273B2 (en) 2017-06-02 2023-12-21 Bayer Healthcare Llc Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer
EP3749654B1 (fr) 2018-02-06 2025-04-23 The Board of Trustees of the University of Illinois Analogues de benzothiophène substitués en tant qu'agents de dégradation sélectifs du récepteur d'oestrogènes
EP4219489A3 (fr) 2018-05-30 2023-11-15 Washington University Inhibiteurs de protéine kinase activée par mitogène, procédés de fabrication et procédés d'utilisation de ceux-ci
CN111053751A (zh) * 2018-10-16 2020-04-24 正大天晴药业集团股份有限公司 瑞戈非尼的缓释片剂及其制备方法
CN109796401B (zh) * 2019-04-04 2023-10-17 新乡双鹭药业有限公司 一种瑞戈非尼原料药的制备方法
MX2022002443A (es) 2019-08-29 2022-06-02 Hibercell Inc Compuestos inhibidores de perk.
GB201913123D0 (en) * 2019-09-11 2019-10-23 Seald As Compositions and methods for treatment of cholangiocarcinoma
EP3861989A1 (fr) 2020-02-07 2021-08-11 Bayer Aktiengesellschaft Composition pharmaceutique contenant du régorafénib et un agent de stabilisation
WO2021160708A1 (fr) 2020-02-14 2021-08-19 Bayer Aktiengesellschaft Combinaison de régorafenib et de msln-ttc pour traiter le cancer
CN112159351B (zh) * 2020-09-21 2021-12-07 广州南鑫药业有限公司 一种多靶点抗肿瘤药物的制备方法
IT202000022636A1 (it) 2020-09-25 2022-03-25 Ente Ospedaliero Specializzato In Gastroenterologia Istituto Nazionale Di Ricovero E Cura A Caratter “terapia di combinazione di sorafenib e/o regorafenib con la proteina ricombinante umana proteoglicano-4 per il trattamento dell'epatocarcinoma”
CN112842998A (zh) * 2021-01-19 2021-05-28 深圳市简一生物科技有限公司 一种瑞戈非尼分散剂及其制备方法
CN117233391A (zh) * 2023-08-28 2023-12-15 南方医科大学南方医院 一种用于预测胃癌免疫治疗和/或化疗疗效的生物标志物及其应用

Family Cites Families (470)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US502504A (en) 1893-08-01 Hermann thoms
US1792156A (en) 1928-01-17 1931-02-10 Gen Aniline Works Inc 5-halogen-2-amino-1-alkyloxy and 1-aralkyloxy-benzenes and intermediate products thereof and process of preparing them
US2093265A (en) 1931-03-31 1937-09-14 Ici Ltd Process for the manufacture of diaryl ureas
US2046375A (en) 1931-06-04 1936-07-07 Ici Ltd p-halogen-omicron-alkoxy-aniline derivatives and process of preparing the same
US2288422A (en) 1938-11-11 1942-06-30 Gen Aniline & Film Corp Mixed ureas
US2973386A (en) 1943-01-05 1961-02-28 Harry A Weldon Purification of sym dichloro-bis (2, 4, 6-trichlorophenyl)urea
US2502504A (en) * 1946-10-18 1950-04-04 John L Botner Hogshead
DE925476C (de) 1950-04-29 1955-03-21 Variapat Ag Verfahren zur Herstellung von farblosen, wasserloeslichen, trifluormethyl- und sulfonsaeuregruppenhaltigen, aliphatischen oder aromatischen Carbonsaeure- bzw. Sulfonsaeurearyliden
US2683082A (en) 1950-12-09 1954-07-06 Ethyl Corp Nu-aryl-nu'-(p-hydroxyphenyl) ureas as antioxidants for petroleum hydrocarbon fuels
US2722544A (en) 1950-12-26 1955-11-01 Variapat Ag Trifluoromethyl halogenated diphenylcarbamide sulfonic acids and their preparation
US2781330A (en) 1953-02-09 1957-02-12 Monsanto Chemicals Rubber containing urea compound as an anti-exposure cracking agent
NL90162C (fr) 1953-03-06
US2745874A (en) 1953-06-18 1956-05-15 Geigy Ag J R Insecticidal derivatives of diphenyl urea
GB771333A (en) 1953-12-22 1957-03-27 Geigy Ag J R Improvements relating to halogen substituted diphenyl urea and thiourea compounds and their use
NL193403A (fr) 1953-12-22 1924-02-17
GB828231A (en) 1955-10-20 1960-02-17 Geigy Ag J R Improvements relating to insecticidal compounds and their use
US2877268A (en) 1956-12-24 1959-03-10 Monsanto Chemicals Substituted ureas
US2960488A (en) 1958-04-25 1960-11-15 Eastman Kodak Co Poly-alpha-olefins containing substituted ureas
NL254871A (fr) 1959-08-14
NL277511A (fr) 1961-04-21
CH428747A (de) 1961-09-11 1967-01-31 Wander Ag Dr A Verfahren zur Herstellung neuer Harnstoff- und Thioharnstoffderivate
US3200035A (en) 1962-06-01 1965-08-10 Ciba Ltd Treatment of synthetic products, especially synthetic fibers
US3284433A (en) 1963-07-17 1966-11-08 Merck & Co Inc 4-phenoxy-carbanilides
FR1457172A (fr) 1964-12-12 1966-10-28 Ferrania Spa Procédé pour la production d'images photographiques en couleurs et matériel photographique correspondant
FR90420E (fr) 1965-06-09 1968-02-21
US3424762A (en) 1966-03-07 1969-01-28 Robins Co Inc A H Certain 3-ureidopyrrolidines
US3424760A (en) 1966-03-07 1969-01-28 Robins Co Inc A H 3-ureidopyrrolidines
US3424761A (en) 1966-03-07 1969-01-28 Robins Co Inc A H 3-ureidopyrrolidines
US3743498A (en) 1967-10-31 1973-07-03 Du Pont Method of selectively controlling undesirable vegetation
US3547940A (en) 1967-10-31 1970-12-15 Du Pont Substituted ureido isoxazoles
SE370866B (fr) 1968-03-21 1974-11-04 Ciba Geigy Ag
DE1768244A1 (de) 1968-04-19 1971-10-14 Bayer Ag N-(2,2,4,4-Tetrafluor-1,3-benz-dioxanyl)-harnstoffe und Verfahren zu ihrer Herstellung
US3646059A (en) 1969-05-05 1972-02-29 Du Pont Plant growth regulatory ureidopyrazoles
US3754887A (en) 1969-05-05 1973-08-28 Du Pont Ureidopyrazoles defoliants
US3668222A (en) 1969-05-14 1972-06-06 Sandoz Ltd 11-desacetoxy-wortmannin
BE754782A (fr) 1969-08-14 1971-02-12 May & Baker Ltd Derives du thiophene a action herbicide
US3823161A (en) 1970-05-07 1974-07-09 Exxon Research Engineering Co Aminothiophene derivatives
US3860645A (en) 1973-05-23 1975-01-14 Givaudan Corp Bacteriostatic substituted carbanilides
US4212981A (en) 1973-07-27 1980-07-15 Shionogi & Co., Ltd. Process for preparing 3-isoxazolylurea derivatives
US4062861A (en) 1973-07-27 1977-12-13 Shionogi & Co., Ltd. 3-Isoxazolylurea derivatives
US4111680A (en) 1973-07-27 1978-09-05 Shionogi & Co., Ltd. Herbicidal compositions containing 3-isoxazolylurea derivatives
JPS5031039A (fr) 1973-07-27 1975-03-27
US4001256A (en) 1973-12-26 1977-01-04 The Upjohn Company Pyridylalkyl phenyl ureas and their n-oxides
US3931201A (en) 1974-01-22 1976-01-06 The Dow Chemical Company Substituted pyridinyloxy(thio)phenyl -acetamides, -ureas and urea derivatives
US4009847A (en) 1974-04-17 1977-03-01 E. I. Du Pont De Nemours And Company 1-Tertiary-alkyl-3-(substituted thienyl)ureas and 1-tertiary-alkyl-3-(substituted thietyl)ureas as antihypertensive agents
US3990879A (en) 1974-12-26 1976-11-09 Eli Lilly And Company Method of controlling aquatic weeds
US4111683A (en) 1975-06-27 1978-09-05 Chevron Research Company N-alkyl or alkoxy-N'-substituted hydrocarbyl urea
DE2637947C2 (de) 1976-08-24 1985-09-19 Bayer Ag, 5090 Leverkusen Tetrafluor-1,3-benzodioxanyl-benzoylharnstoffe, Verfahren zu ihrer Herstellung und ihre Verwendung als Insektizide
JPS5840946B2 (ja) 1976-10-29 1983-09-08 石原産業株式会社 Ｎ−ベンゾイル−ｎ′−ピリジルオキシフエニルウレア系化合物、それらの製造方法及びそれらを含有する殺虫剤
US4173637A (en) 1976-10-29 1979-11-06 Ishihara Sangyo Kaisha Ltd. N-Benzoyl-N'-pyridyloxy phenyl urea and insecticidal compositions thereof
US4071524A (en) 1976-11-08 1978-01-31 Riker Laboratories, Inc. Derivatives of urea
US4183854A (en) 1976-11-10 1980-01-15 John Wyeth & Brother Limited Thiazole compound
US4042372A (en) 1976-11-19 1977-08-16 Eli Lilly And Company Substituted thiadiazolotriazinediones and method of preparation
DE2817449A1 (de) 1978-04-21 1979-10-31 Bayer Ag Mittel zur regulierung des pflanzenwachstums
GB1590870A (en) 1978-05-31 1981-06-10 Shionogi & Co N-(5-t-butyl-3-isoxazolyl) alkanamide derivatives having herbicidal activity
JPS5562066A (en) 1978-11-03 1980-05-10 Toshihiko Okamoto N-(2-substituted-4-pyridyl)-urea and thio urea, their preparation and plant growth regulator
DE2848330A1 (de) 1978-11-03 1980-05-14 Schering Ag Verfahren zur herstellung von 1,2, 3-thiadiazol-5-yl-harnstoffen
FI800559A7 (fi) 1979-03-14 1981-01-01 F Hoffmann La Roche & Co Virtsa-ainejohdannaiset.
JPS55124763A (en) 1979-03-19 1980-09-26 Ishihara Sangyo Kaisha Ltd 5-trifluoromethyl-2-pyridone derivative
DE2928485A1 (de) 1979-07-14 1981-01-29 Bayer Ag Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen
US4468380A (en) 1979-12-26 1984-08-28 Eli Lilly And Company Anticoccidial combinations comprising polyether antibiotics and carbanilides
WO1981002156A1 (fr) 1980-01-25 1981-08-06 Reanal Finomvegyszergyar Procede de preparation de derives de n-aryle-n'-uree mono ou disubstitues
ATE9131T1 (de) 1980-05-14 1984-09-15 Ciba-Geigy Ag Phenylbenzoylharnstoffe.
EP0057797B1 (fr) 1981-02-03 1986-06-25 Imperial Chemical Industries Plc Procédé pour l'extraction de métaux et agents d'extraction pour métaux
US4526997A (en) 1981-05-06 1985-07-02 Doherty George O P O Anticoccidial combinations comprising polyether antibiotics and carbanilides
US4511571A (en) 1981-10-20 1985-04-16 Ciba Geigy Corporation N-(2-Pyridyloxyphenyl)-N'-benzoyl ureas, pesticidal compositions containing same and pesticidal methods of use
US4473579A (en) 1982-01-26 1984-09-25 American Cyanamid Company Antiatherosclerotic tetrasubstituted ureas and thioureas
US4623662A (en) 1985-05-23 1986-11-18 American Cyanamid Company Antiatherosclerotic ureas and thioureas
DE3211851A1 (de) 1982-03-31 1983-10-06 Basf Ag Dihydrothiophen-carbonester, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses
JPS58203957A (ja) 1982-05-25 1983-11-28 Ube Ind Ltd 尿素誘導体の製法
IL69621A0 (en) 1982-09-02 1983-12-30 Duphar Int Res Pharmaceutical compositions having antitumor activity,comprising certain phenylurea derivatives
CA1254212A (fr) 1982-11-12 1989-05-16 Shiro Hirai Amines derives, leur sels, procede de preparation et agent anti-ulcereux les contenant
DE3305866A1 (de) 1983-02-19 1984-08-23 Basf Ag, 6700 Ludwigshafen Thiophen-carbonester, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses
US4499097A (en) 1983-03-10 1985-02-12 American Cyanamid Company 2-(Pyridyl)imidazolyl ketones
GB8325496D0 (en) 1983-09-23 1983-10-26 Hider R C Pharmaceutical compositions
CH663353A5 (de) 1984-03-28 1987-12-15 Joaquin Amat Larraz Mittel gegen krebs.
US4540566A (en) 1984-04-02 1985-09-10 Forest Laboratories, Inc. Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose
JPS6193163A (ja) 1984-10-12 1986-05-12 Ishihara Sangyo Kaisha Ltd Ｎ−ベンゾイル−ｎ′−フエニルウレア系化合物、それらの製造方法並びにそれらを含有する抗癌剤
US4727077A (en) 1985-02-20 1988-02-23 Ishihara Sangyo Kaisha Ltd. Benzoyl urea compounds, process for their production, and antitumorous compositions containing them
DE3529247A1 (de) 1985-05-17 1986-11-20 Bayer Ag, 5090 Leverkusen Verwendung von thienylharnstoffen und -isoharnstoffen als leistungsfoerdernde mittel bei tieren, neue thienylharnstoffe und -isoharnstoffe und ihre herstellung
DE3540377A1 (de) 1985-11-14 1987-05-21 Bayer Ag Thienooxazinone, verfahren zu ihrer herstellung und ihre verwendung als leistungsfoerderer
DE3541631A1 (de) 1985-11-26 1987-05-27 Bayer Ag Selektiv-fungizide verwendung von thienylharnstoff-derivaten
AU594098B2 (en) 1985-12-11 1990-03-01 Ishihara Sangyo Kaisha Ltd. N-benzoyl urea compounds, antitumorous compositions containing them, and process for their preparation
EP0230400A3 (fr) 1986-01-21 1990-02-14 Ciba-Geigy Ag N-3-(5-Trifluorométhyl-pyridyl-2-oxy)phényl-N'-benzoylureds pour combattre des helminths chez le bétail
JPS62185013A (ja) 1986-02-08 1987-08-13 Green Cross Corp:The 易吸収性医薬組成物
DE3612830A1 (de) 1986-04-16 1987-10-22 Basf Ag Thiadiazolylharnstoff enthaltendes mittel zur entblaetterung von pflanzen
DE3785507T2 (de) 1986-07-31 1993-07-29 Beecham Group Plc Azabicyclische verbindungen, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung.
EP0262560A3 (fr) 1986-09-29 1989-07-05 Ishihara Sangyo Kaisha, Ltd. Composés benzoyl urées
US4835180A (en) 1986-10-02 1989-05-30 Sterling Drug Inc. N-(ω-cyanoalkyl)aminophenols and use as inhibitors of lipoxygenase activity
NZ221964A (en) 1986-10-03 1990-03-27 Ishihara Sangyo Kaisha Benzoylurea compounds and insecticidal compositions
US4983605A (en) 1986-10-23 1991-01-08 Ishihara Sangyo Kaisha Ltd. Pharmaceutical composition
DE3636190A1 (de) 1986-10-24 1988-04-28 Bayer Ag Verfahren zur herstellung von n,n-diaryl-harnstoffen
JPH06100808B2 (ja) 1987-05-28 1994-12-12 富士写真フイルム株式会社 ハロゲン化銀カラ−写真感光材料の処理方法
DE3810382A1 (de) 1988-03-26 1989-10-12 Bayer Ag 5-amino-1-phenylpyrazole, verfahren sowie 5-halogen-1-phenylpyrazole als zwischenprodukte zu deren herstellung und ihre verwendung als herbizide
WO1990002112A1 (fr) 1988-08-23 1990-03-08 The Nutrasweet Company Arylurees substituees utilisees comme edulcorants de forte puissance
JPH0278699A (ja) 1988-09-12 1990-03-19 Green Cross Corp:The ベンゾイルウレア系化合物・アルブミン複合体
FR2639636B1 (fr) 1988-11-30 1994-03-04 Novapharme Nouveaux composes heterocycliques a activite anticonvulsivante, procede de preparation et compositions therapeutiques les contenant
FR2662692B1 (fr) 1990-05-30 1995-04-28 Novapharme Derives heterocycliques doues d'activite anticonvulsivante, procede de preparation et composition pharmaceutique.
JPH02196719A (ja) 1989-01-24 1990-08-03 Green Cross Corp:The 粉末状医薬組成物
JPH02237922A (ja) 1989-01-24 1990-09-20 Green Cross Corp:The 抗ウィルス剤
EP0379915A1 (fr) 1989-01-26 1990-08-01 Bayer Ag Dérivés substitués du phénoxybenzonitrile, procédés pour leur préparation et leur utilisation comme herbicides et comme régulateurs de la croissance des plantes
JP3002204B2 (ja) 1989-03-13 2000-01-24 株式会社東芝 時系列信号認識装置
US4973675A (en) 1989-04-13 1990-11-27 University Of Tennessee Research Center Hybrid nitrosoureidoanthracyclines having antitumor activity
JPH0395153A (ja) 1989-06-15 1991-04-19 Mitsubishi Kasei Corp ジフェニル尿素誘導体
US5665543A (en) 1989-07-18 1997-09-09 Oncogene Science, Inc. Method of discovering chemicals capable of functioning as gene expression modulators
IL95860A0 (en) 1989-10-13 1991-07-18 Ciba Geigy Ag Thienylthioureas,-isothioureas and-carbodiimides
EP0425443A1 (fr) 1989-10-27 1991-05-02 Ciba-Geigy Ag Agent antiparasitaire injectable
DK40890D0 (da) 1990-02-16 1990-02-16 Ferrosan As Substituerede urinstofforbindelser, deres fremstilling og anvendelse
US5399566A (en) 1990-06-19 1995-03-21 Meiji Seika Kabushiki Kaisha Pyridine derivatives having angiotensin II antagonism
GB9017892D0 (en) 1990-08-15 1990-09-26 May & Baker Ltd New compositions of matter
EP0525197B1 (fr) 1991-01-21 1997-08-27 Shionogi Seiyaku Kabushiki Kaisha Analogues de 3-benzylidene-1-carbamoyl-2-pyrrolidone
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5185438A (en) 1991-04-02 1993-02-09 The Trustees Of Princeton University Nucleic acids encoding hencatoporetic stem cell receptor flk-2
US5270458A (en) 1991-04-02 1993-12-14 The Trustees Of Princeton University Nucleic acids encoding fragments of hematopoietic stem cell receptor flk-2
US5100883A (en) 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
JPH05112573A (ja) 1991-04-17 1993-05-07 American Home Prod Corp ラパマイシンのカルバミン酸エステル類
US5118678A (en) 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5118677A (en) 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
US5162360A (en) 1991-06-24 1992-11-10 Warner-Lambert Company 2-heteroatom containing urea and thiourea ACAT inhibitors
US5185358A (en) 1991-06-24 1993-02-09 Warner-Lambert Co. 3-heteroatom containing urea and thiourea ACAT inhibitors
WO1993004170A1 (fr) 1991-08-23 1993-03-04 The United States Of America Represented By The Secretary, Department Of Health And Human Services Therapeutique a base de kinases de la proteine raf
US5151413A (en) 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
US5254582A (en) 1992-02-05 1993-10-19 Eli Lilly And Company Antitumor compositions and methods
EP0630373A1 (fr) 1992-03-12 1994-12-28 Smithkline Beecham Plc Derives d'indole utilises comme antagonistes de 5ht 1c?
US6001860A (en) 1992-05-28 1999-12-14 Pfizer Inc. N-aryl and N-heteroarylurea derivatives as inhibitors of acyl coenzyme A: Cholesterol acyl transferase (ACAT)
US5312820A (en) 1992-07-17 1994-05-17 Merck & Co., Inc. Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines
US5256790A (en) 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
JP2717481B2 (ja) 1992-08-25 1998-02-18 富士写真フイルム株式会社 ハロゲン化銀カラー写真感光材料
CN2146707Y (zh) 1992-09-08 1993-11-17 华东冶金学院 高炉软水冷却系统检漏装置
US5258389A (en) 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
WO1994014801A1 (fr) 1992-12-29 1994-07-07 Smithkline Beecham Plc Derives heterocycliques de l'uree antagonistes de 5ht2c et 5h¿2b?
US5512473A (en) 1993-01-29 1996-04-30 Brent; Roger Max-interacting proteins and related molecules and methods
GB9302275D0 (en) 1993-02-05 1993-03-24 Smithkline Beecham Plc Novel compounds
TW272942B (fr) 1993-02-10 1996-03-21 Takeda Pharm Industry Co Ltd
DK41193D0 (da) 1993-04-07 1993-04-07 Neurosearch As Ionkanalaabnere
DE4322806A1 (de) 1993-07-08 1995-01-12 Janich Gmbh & Co Vorrichtung zur Abdichtung zwischen zwei Anlagenteilen
IL110296A (en) 1993-07-16 1999-12-31 Smithkline Beecham Corp Imidazole compounds process for their preparation and pharmaceutical compositions containing them
US5378725A (en) 1993-07-19 1995-01-03 The Arizona Board Of Regents Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof
US6514745B1 (en) 1993-07-19 2003-02-04 The Regents Of The University Of California Oncoprotein protein kinase
NZ264063A (en) 1993-08-13 1995-11-27 Nihon Nohyaku Co Ltd N-(2-phenylpyrid-3-yl)- and n-(4-phenylpyrimidin-5-yl)-n'-phenylurea derivatives and pharmaceutical compositions
US5441947A (en) 1993-08-25 1995-08-15 Eli Lilly And Company Methods of inhibiting vascular restenosis
US5504103A (en) 1993-08-25 1996-04-02 Eli Lilly And Company Inhibition of phosphatidylinositol 3-kinase with 17 β-hydroxywortmannin and analogs thereof
US5468773A (en) 1993-08-25 1995-11-21 Eli Lilly And Company Methods for inhibiting bone loss and cartilage degradation using wortmannin and its analogs
US5869043A (en) 1993-09-17 1999-02-09 Smithkline Beecham Corporation Drug binding protein
US6361773B1 (en) 1993-09-17 2002-03-26 Smithkline Beecham Corporation Antibodies produced against cytokine suppressive anti-inflammatory drug binding proteins
US5783664A (en) 1993-09-17 1998-07-21 Smithkline Beecham Corporation Cytokine suppressive anit-inflammatory drug binding proteins
CA2171982C (fr) 1993-09-17 2000-02-01 John Cheung-Lun Lee Proteine de liaison de medicament
US5547966A (en) 1993-10-07 1996-08-20 Bristol-Myers Squibb Company Aryl urea and related compounds
CA2133815A1 (fr) 1993-10-12 1995-04-13 Jeffrey Alan Dodge Inhibition de la phosphatidylinositol 3-kinase au moyen de la viridine, de la demethoxyviridine, du viridiol, du demethoxyviridiol, de la virone et de la wortmannolone et analogues de ces substances.
US5596001A (en) 1993-10-25 1997-01-21 Pfizer Inc. 4-aryl-3-(heteroarylureido)quinoline derivatves
WO1995013067A1 (fr) 1993-11-08 1995-05-18 Smithkline Beecham Corporation Oxazoles pour le traitement de maladies induites par la cytokine
JPH07141053A (ja) 1993-11-17 1995-06-02 Nec Niigata Ltd クロック発生回路
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
CH686211A5 (de) 1994-01-27 1996-02-15 Ciba Geigy Ag Motten- und Koferschutzmittel.
US6524832B1 (en) 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
US6811779B2 (en) * 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
DE4412334A1 (de) 1994-04-11 1995-10-19 Hoechst Ag Substituierte N-Heteroaroylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
US5559137A (en) 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds
US5656612A (en) 1994-05-31 1997-08-12 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US5744362A (en) 1994-05-31 1998-04-28 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
WO1995033458A1 (fr) 1994-06-02 1995-12-14 Smithkline Beecham Corporation Composes anti-inflammatoires
US5470882A (en) 1994-06-02 1995-11-28 Smithkline Beecham Corp. Anti-inflammatory compounds
US5447957A (en) 1994-06-02 1995-09-05 Smithkline Beecham Corp. Anti-inflammatory compounds
US5786362A (en) 1994-06-16 1998-07-28 University Of Miami Method of treating Hormone independent cancer
EP0690344A1 (fr) 1994-06-29 1996-01-03 Konica Corporation Matériau photographique à couleurs à l'halogénure d'argent sensible à la lumière
US5480906A (en) 1994-07-01 1996-01-02 Eli Lilly And Company Stereochemical Wortmannin derivatives
FR2722319B1 (fr) 1994-07-08 1996-08-14 Thomson Csf Dispositif de visualisation couleurs
US5597719A (en) 1994-07-14 1997-01-28 Onyx Pharmaceuticals, Inc. Interaction of RAF-1 and 14-3-3 proteins
AU3577995A (en) 1994-10-04 1996-04-26 Fujisawa Pharmaceutical Co., Ltd. Urea derivatives and their use as acat-inhibitors
ES2180600T3 (es) 1994-10-19 2003-02-16 Novartis Ag Eteres de isosteros substrato de aspartato proteasa antivirales.
CA2161376C (fr) 1994-10-27 2005-01-11 Toshiaki Minami Support d'enregistrement thermique multicolore reversible
EP0788564B1 (fr) 1994-10-28 2001-05-16 Novozymes A/S Procede d'appret chimique de fibres polymeres insolubles
TW313568B (fr) 1994-12-20 1997-08-21 Hoffmann La Roche
FR2729567B1 (fr) * 1995-01-20 1997-06-13 Oreal Composition de teinture d'oxydation des fibres keratiniques et procede de teinture mettant en oeuvre cette composition
EP0809492A4 (fr) 1995-02-17 2007-01-24 Smithkline Beecham Corp Antagonistes des recepteurs d'il-8
US5780483A (en) 1995-02-17 1998-07-14 Smithkline Beecham Corporation IL-8 receptor antagonists
US5624937A (en) 1995-03-02 1997-04-29 Eli Lilly And Company Chemical compounds as inhibitors of amyloid beta protein production
US5814646A (en) 1995-03-02 1998-09-29 Eli Lilly And Company Inhibitors of amyloid beta-protein production
DE19512639A1 (de) 1995-04-05 1996-10-10 Merck Patent Gmbh Benzonitrile und -fluoride
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5710173A (en) 1995-06-07 1998-01-20 Sugen, Inc. Thienyl compounds for inhibition of cell proliferative disorders
IL118544A (en) 1995-06-07 2001-08-08 Smithkline Beecham Corp History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
US5773459A (en) 1995-06-07 1998-06-30 Sugen, Inc. Urea- and thiourea-type compounds
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
CZ272296A3 (en) 1995-09-18 1997-04-16 Sankyo Co Novel derivatives of urea exhibiting acat inhibition activity, their preparation and therapeutic and prophylactic application
SE510846C2 (sv) 1995-11-06 1999-06-28 Moelnlycke Health Care Ab Innerförpackning för i en yttre förpackning sterilförpackade bukdukar
AU7340096A (en) 1995-11-07 1997-05-29 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
CA2241528A1 (fr) 1995-12-28 1997-07-10 Hisashi Kanno Nouveaux n-(non substitue ou substitue)-4-substitue-6-(non substitue ou substitue) phenoxy-2-pyridinecarboxamides ou thiocarboxamides, leurs procedes de production, et herbicides
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6005008A (en) 1996-02-16 1999-12-21 Smithkline Beecham Corporation IL-8 receptor antagonists
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
US6103692A (en) 1996-03-12 2000-08-15 The General Hospital Corporation Inhibiting protein interactions
US6262113B1 (en) 1996-03-20 2001-07-17 Smithkline Beecham Corporation IL-8 receptor antagonists
US6211373B1 (en) 1996-03-20 2001-04-03 Smithkline Beecham Corporation Phenyl urea antagonists of the IL-8 receptor
ATE189814T1 (de) 1996-04-15 2000-03-15 Takeda Chemical Industries Ltd Hydroxypyridin-derivate, ihre herstellung und ihre pharmazeutische verwendung
PL192628B1 (pl) 1996-04-23 2006-11-30 Vertex Pharma Pochodne mocznika, kompozycje farmaceutyczne i zastosowanie związku i kompozycji
US6232299B1 (en) 1996-05-01 2001-05-15 Eli Lilly And Company Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
JPH09301858A (ja) 1996-05-13 1997-11-25 Senju Pharmaceut Co Ltd グルコン酸クロルヘキシジン安定化水性薬剤
DE69716424T2 (de) 1996-05-24 2003-02-20 Neurosearch A/S, Ballerup Saure gruppen enthaltende phenylderivate, ihre herstellung und ihre verwendung als chloridkanalblocker
US5910417A (en) 1996-05-31 1999-06-08 National Jewish Center For Immunology And Respiratory Medicine Regulation of cytokine production in a hematopoietic cell
EP0907362A4 (fr) 1996-06-27 1999-12-01 Smithkline Beecham Corp Antagonistes des recepteurs d'il-8
BR9709938A (pt) 1996-06-27 1999-08-10 Smithkline Beecham Corp Antagonistas dos receptores de il-8
US6218539B1 (en) 1996-06-27 2001-04-17 Smithkline Beecham Corporation IL-8 receptor antagonists
IL127666A0 (en) 1996-06-27 1999-10-28 Smithkline Beecham Corp IL-8 receptor antagonists
US6150415A (en) 1996-08-13 2000-11-21 The Regents Of The University Of California Epoxide hydrolase complexes and methods therewith
US5808080A (en) 1996-09-05 1998-09-15 Eli Lilly And Company Selective β3 adrenergic agonists
WO1998017207A1 (fr) 1996-10-21 1998-04-30 Synthes Ag Chur Prothese chirurgicale
US5965573A (en) 1996-10-23 1999-10-12 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
EP0973513A4 (fr) 1996-10-23 2003-03-19 Zymogenetics Inc Compositions et methodes pour traiter les etats associes a un deficit osseux
EP0963197B1 (fr) 1996-11-15 2010-01-06 Cytokine PharmaSciences, Inc. Guanylhydrazones utiles dans le traitement de maladies associees a l'activation des cellules t
GB9623833D0 (en) 1996-11-16 1997-01-08 Zeneca Ltd Chemical compound
AU4966497A (en) 1996-11-18 1998-06-10 Yamanouchi Pharmaceutical Co., Ltd. Novel acylamino-substituted acylanilide derivatives or pharmaceutical composition comprising the same
FR2755967B1 (fr) 1996-11-21 1999-01-29 Pf Medicament Derives de la pyridin-2-yl-methylamine, leur procede de preparation et leur application comme medicaments
CN1217660C (zh) 1997-01-23 2005-09-07 史密丝克莱恩比彻姆公司 Il－8受体拮抗剂
US5929250A (en) 1997-01-23 1999-07-27 Smithkline Beecham Corporation IL-8 receptor antagonists
DE19706061A1 (de) 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
ES2224365T3 (es) 1997-02-12 2005-03-01 Smithkline Beecham Corporation Antagonistas de receptores de il-8.
CN1254335A (zh) 1997-04-04 2000-05-24 辉瑞产品公司 烟酰胺衍生物
ATE298741T1 (de) 1997-04-10 2005-07-15 Pharmacia & Upjohn Co Llc Polyaromatische verbindungen zur behandlung von herpes-infektionen
WO1998049150A1 (fr) 1997-04-25 1998-11-05 Takeda Chemical Industries, Ltd. Derives de triazine, production de ces produits et composition agrochimique
US6210710B1 (en) 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US6316479B1 (en) 1997-05-19 2001-11-13 Sugen, Inc. Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
CA2288741A1 (fr) 1997-05-22 1998-11-26 G.D. Searle And Co. Pyrazoles 3(5)-heteroaryl substituees utilisees comme inhibiteurs de kinase p38
AU7726898A (en) 1997-05-22 1998-12-11 G.D. Searle & Co. Pyrazole derivatives as p38 kinase inhibitors
US6344476B1 (en) 1997-05-23 2002-02-05 Bayer Corporation Inhibition of p38 kinase activity by aryl ureas
AU7585598A (en) 1997-05-23 1998-12-11 Bayer Corporation Raf kinase inhibitors
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
DE69826695T2 (de) 1997-05-23 2006-02-02 Bayer Pharmaceuticals Corp., West Haven Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
US6150395A (en) 1997-05-30 2000-11-21 The Regents Of The University Of California Indole-3-carbinol (I3C) derivatives and methods
US6294350B1 (en) 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
US5985592A (en) 1997-06-05 1999-11-16 Dalhousie University Uses for pentoxifylline or functional derivatives/metabolites thereof
EP1023066A4 (fr) 1997-06-13 2001-05-23 Smithkline Beecham Corp Nouveaux composes de pyrazole et de pyrazoline substitues
US6093742A (en) 1997-06-27 2000-07-25 Vertex Pharmaceuticals, Inc. Inhibitors of p38
WO1999000370A1 (fr) 1997-06-27 1999-01-07 Kureha Kagaku Kogyo Kabushiki Kaisha Acide 6-phenoxypicolinique, derives d'alkylidenehydrazide, leur procede de production, et herbicide
US6525065B1 (en) 1997-06-30 2003-02-25 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
AUPP003197A0 (en) 1997-09-03 1997-11-20 Fujisawa Pharmaceutical Co., Ltd. New heterocyclic compounds
UA71555C2 (en) 1997-10-06 2004-12-15 Zentaris Gmbh Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
AU9802198A (en) 1997-10-21 1999-05-10 Pharmacia & Upjohn Company Antiinflammatory thiadiazolyl ureas which act as lfa-1 and mac-1 inhibitors
BR9813331A (pt) 1997-10-31 2000-08-22 Aventis Pharma Ltd Composto, uso do mesmo, composição farmacêutica, processo para o tratamento de um paciente humano ou animal não humano que sofra ou esteja sujeito a condições que possam ser melhoradas pela administração de um inibidor da adesão celular mediada pela a4b1, e, resina
JP2001521934A (ja) 1997-11-03 2001-11-13 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 抗炎症薬としての芳香族ヘテロ環式化合物
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6018065A (en) 1997-11-10 2000-01-25 Advanced Technology Materials, Inc. Method of fabricating iridium-based materials and structures on substrates, iridium source reagents therefor
GB9723789D0 (en) 1997-11-12 1998-01-07 Zeneca Ltd Chemical compounds
WO1999026657A1 (fr) 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibiteurs de la monoxyde d'azote-synthase
AU1407899A (en) 1997-12-01 1999-06-16 E.I. Du Pont De Nemours And Company Fungicidal cyclic amides
US6635421B1 (en) 1997-12-09 2003-10-21 Children's Medical Center Corporation Neuropilins and use thereof in methods for diagnosis and prognosis of cancer
US6174901B1 (en) 1998-12-18 2001-01-16 Amgen Inc. Substituted pyridine and pyridazine compounds and methods of use
SK282727B6 (sk) 1997-12-19 2002-11-06 Slovakofarma, A. S. 1,3-Disubstituované močoviny - inhibítory ACAT a spôsob ich prípravy
RU2265597C2 (ru) 1997-12-22 2005-12-10 Байер Копэрейшн Арил- и гетероарилзамещенные гетероциклические производные мочевины, способ ингибирования киназы raf и фармацевтическая композиция
US20120046290A1 (en) 1997-12-22 2012-02-23 Jacques Dumas Inhibition of p38 kinase activity using substituted heterocyclic ureas
DK1047418T3 (da) 1997-12-22 2005-11-21 Bayer Pharmaceuticals Corp Inhibering af raf-kinase ved hjælp af substituerede heterocykliske urinstoffer
US20070244120A1 (en) 2000-08-18 2007-10-18 Jacques Dumas Inhibition of raf kinase using substituted heterocyclic ureas
CN1213022C (zh) 1997-12-22 2005-08-03 拜尔有限公司 用对称和不对称的取代二苯脲抑制raf激酶
DK1043995T3 (da) 1997-12-22 2007-03-05 Bayer Pharmaceuticals Corp Inhibering af p38 kinaseaktivitet ved anvendelse af aryl- og heteroaryl-substituerede, heterocykliske urinstoffer
CA2315720A1 (fr) 1997-12-22 1999-07-01 Bayer Corporation Inhibition de l'activite de p38 kinase au moyen d'urees heterocycliques substituees
CA2315715C (fr) 1997-12-22 2010-06-22 Bayer Corporation Inhibition de la kinase p38 par des diphenyl-urees symetriques et dissymetriques
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US20080300281A1 (en) 1997-12-22 2008-12-04 Jacques Dumas Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
EP1043020A1 (fr) 1997-12-25 2000-10-11 Daiichi Pharmaceutical Co., Ltd. Composition medicinale pour administration percutanee
JP2001501979A (ja) 1998-01-21 2001-02-13 ザイモジェネティクス，インコーポレイティド カルシトニン擬態物としてのジアルキルウレア
FR2774824B1 (fr) 1998-02-09 2000-04-28 Moving Magnet Tech Actionneur lineaire ameliore
AU2630199A (en) 1998-02-18 1999-09-06 Theryte Limited Treating cancer
MY132496A (en) 1998-05-11 2007-10-31 Vertex Pharma Inhibitors of p38
US6413773B1 (en) 1998-06-01 2002-07-02 The Regents Of The University Of California Phosphatidylinositol 3-kinase inhibitors as stimulators of endocrine differentiation
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
US6667340B1 (en) 1998-06-26 2003-12-23 Arizona Board Of Regents On Behalf Of The University Of Arizona Inhibitors of phosphatidyl myo-inositol cycle
US6352977B1 (en) 1998-07-13 2002-03-05 Aventis Pharma Limited Substituted β-alanines
AU762245B2 (en) 1998-09-18 2003-06-19 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US6383734B1 (en) 1998-09-30 2002-05-07 Advanced Research And Technology Institute, Inc. Method to determine inhibition of PAK3 activation of Raf-1
US6130053A (en) 1999-08-03 2000-10-10 Cell Pathways, Inc. Method for selecting compounds for inhibition of neoplastic lesions
GB9823873D0 (en) 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
JP2002529421A (ja) 1998-11-06 2002-09-10 ビーエーエスエフ アクチェンゲゼルシャフト 血管過浸透性の阻害方法
WO2000031238A2 (fr) 1998-11-25 2000-06-02 Genetica, Inc. Methodes et reactifs d'augmentation de la capacite proliferative et de prevention de la senescence replicative
US6114517A (en) 1998-12-10 2000-09-05 Isis Pharmaceuticals Inc. Methods of modulating tumor necrosis factor α-induced expression of cell adhesion molecules
US6337338B1 (en) 1998-12-15 2002-01-08 Telik, Inc. Heteroaryl-aryl ureas as IGF-1 receptor antagonists
UY25842A1 (es) 1998-12-16 2001-04-30 Smithkline Beecham Corp Antagonistas de receptores de il-8
US6331541B1 (en) 1998-12-18 2001-12-18 Soo S. Ko N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AU3126700A (en) 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6147107A (en) 1998-12-20 2000-11-14 Virginia Commonwealth University Specific inhibition of the P42/44 mitogen activated protein (map) kinase cascade sensitizes tumor cells
US20080269265A1 (en) 1998-12-22 2008-10-30 Scott Miller Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
ATE301116T1 (de) 1998-12-25 2005-08-15 Teikoku Hormone Mfg Co Ltd Aminopyrazol derivate
EP1140840B1 (fr) * 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. Diphenylurees a substituants -g(v)-carboxyaryles, inhibitrices de kinase raf
US20020065296A1 (en) 1999-01-13 2002-05-30 Bayer Corporation Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
ATE538794T1 (de) 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
RU2319693C9 (ru) 1999-01-13 2008-08-20 Байер Копэрейшн Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты)
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
TWI284642B (en) 1999-01-18 2007-08-01 Hoffmann La Roche Novel heterocyclic sulfonamides
UA73492C2 (en) 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
EP1384712B1 (fr) 1999-01-22 2007-03-07 Kirin Beer Kabushiki Kaisha Derivés de la N-((quinolinyl)oxy)-phenyl)-urée et de la N-((quinazolinyl)oxy)-phenyl)-urée avec activité antitumorale
ES2226785T3 (es) 1999-02-12 2005-04-01 Smithkline Beecham Plc Derivados de fenilurea como antagonistas de los receptores de orexina.
WO2000050425A1 (fr) 1999-02-22 2000-08-31 Boehringer Ingelheim Pharmaceuticals, Inc. Derives polycyclo heterocycliques utilises en tant qu'agents anti-inflammatoires
ID30176A (id) 1999-03-12 2001-11-08 Boehringer Ingelheim Pharma Senyawa-senyawa yang bermanfaat sebagai zat anti-inflamasi
EP1163236B1 (fr) 1999-03-12 2005-11-09 Boehringer Ingelheim Pharmaceuticals Inc. Composes aromatiques heterocycliques utilises en tant qu'agents anti-inflammatoires
AU769383B2 (en) 1999-03-19 2004-01-22 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
ES2345921T3 (es) 1999-03-26 2010-10-06 Euro-Celtique S.A. Pirazoles, imidazoles, oxazoles, tiazoles y pirroles sustituidos con arilo y su uso.
US6140124A (en) 1999-04-06 2000-10-31 Isis Pharmaceuticals Inc. Antisense modulation of P38 mitogen activated protein kinase expression
US6316462B1 (en) 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
WO2000068223A1 (fr) 1999-05-05 2000-11-16 Aventis Pharma Limited Urees en tant que modulateurs de l'adhesion cellulaire
HUP0201480A3 (en) 1999-05-14 2009-03-30 Imclone Systems Inc Treatment of refractory human tumors with epidermal growth factor receptor antagonists
HN2000000051A (es) 1999-05-19 2001-02-02 Pfizer Prod Inc Derivados heterociclicos utiles como agentes anticancerosos
TWI234557B (en) 1999-05-26 2005-06-21 Telik Inc Novel naphthalene ureas as glucose uptake enhancers
DE19927835A1 (de) 1999-06-18 2000-12-21 Clariant Gmbh Verwendung von verbesserten Cyanpigmenten in elektrophotographischen Tonern und Entwicklern, Pulverlacken und Ink-Jet-Tinten
EP1200411B1 (fr) 1999-07-09 2005-12-14 Boehringer Ingelheim Pharmaceuticals Inc. Procede de synthese de composes d'uree a substitution heteroaryle
EP1209578B1 (fr) 1999-07-09 2007-02-14 Niigata Seimitsu Co., Ltd. Dispositif de generation de donnees sur forme d'onde a fonction d'echantillonnage
DE60024631T2 (de) 1999-07-26 2006-06-14 Banyu Pharma Co Ltd Biaryl-harnstoff-derivate
WO2001009088A1 (fr) 1999-07-28 2001-02-08 Kirin Beer Kabushiki Kaisha Derives d'uree utilises comme inhibiteurs du recepteur ccr-3
US6387900B1 (en) 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
US6372933B1 (en) 1999-08-26 2002-04-16 Smithkline Beecham Corporation Process for preparing certain phenyl urea compounds
MXPA02003742A (es) 1999-10-15 2003-10-14 Kampen Group Inc Van Tratamiento de tumores dermicos, verrugas e infecciones virales usando p. acnes muerto por calor.
CA2389360C (fr) 1999-11-16 2008-06-03 Steffen Breitfelder Derives d'uree utilises comme agents anti-inflammatoires
US6525046B1 (en) 2000-01-18 2003-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as antiinflammatory agents
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
SK12712002A3 (sk) 2000-02-07 2003-02-04 Abbott Gmbh & Co. Kg Deriváty 2-benzotiazolylmočoviny a ich použitie ako inhibítorov proteínkináz
US6608052B2 (en) 2000-02-16 2003-08-19 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
CA2401665A1 (fr) 2000-03-02 2001-09-07 Ludwig Institute For Cancer Research Procedes de traitement, d'examen et de detection de cancers exprimant le facteur d de croissance endotheliale vasculaire
GB0005357D0 (en) 2000-03-06 2000-04-26 Smithkline Beecham Plc Compounds
BR0110310A (pt) 2000-04-19 2003-02-18 Fujisawa Pharmaceutical Co Dispersão sólida, processo para sua produção e preparado farmacêutico contendo a mesma
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US6403588B1 (en) 2000-04-27 2002-06-11 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
WO2002007008A1 (fr) 2000-04-28 2002-01-24 Ubink Cornelis Hubertus Johann Systeme d'approvisionnement en reseau
US6390102B1 (en) 2000-07-14 2002-05-21 General Electric Company Silicone compositions for personal care products and method for making
US7175844B2 (en) 2000-07-18 2007-02-13 Joslin Diabetes Center, Inc. Methods of modulating fibrosis
US6565880B2 (en) 2000-07-24 2003-05-20 Boehringer Ingelheim Pharmaceuticals, Inc. Oral dosage formulations of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea
GT200100147A (es) 2000-07-31 2002-06-25 Derivados de imidazol
CA2417310A1 (fr) 2000-08-04 2002-02-14 Wolff M. Kirsch Proteine 2 de regulation du fer (irp-2) utilisee dans le diagnostic de maladies neurodegeneratives
CA2418389A1 (fr) 2000-08-11 2002-02-21 Vertex Pharmaceuticals Incorporated Derives de pyridine comme inhibiteurs de p38
US20020173507A1 (en) 2000-08-15 2002-11-21 Vincent Santora Urea compounds and methods of uses
ATE316977T1 (de) 2000-08-17 2006-02-15 Kitasato Inst Neue pseudoerythromycin derivate
EP1313710A1 (fr) 2000-08-31 2003-05-28 Pfizer Products Inc. Derives pyrazole et leur utilisation en tant qu'inhibiteurs des proteines kinases
AUPR034000A0 (en) 2000-09-25 2000-10-19 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
EP1506962B1 (fr) 2000-10-20 2008-07-02 Eisai R&D Management Co., Ltd. Hétérocycles aromatiques contenant de l'azote
JP3768800B2 (ja) 2000-10-31 2006-04-19 キヤノン株式会社 画像形成装置
AU2002223500A1 (en) 2000-11-17 2002-05-27 Novo-Nordisk A/S Glucagon antagonists/inverse agonists
CN1525889A (zh) 2000-11-27 2004-09-01 ����ˡ�A�������� 分类物品的系统、方法及程序
WO2002044158A1 (fr) 2000-11-28 2002-06-06 Pfizer Products Inc. Sels d'un isothiazole-4-carboxamide et leur utilisation comme agents anti-hyperproliferatifs
JP2004517080A (ja) 2000-11-29 2004-06-10 グラクソ グループ リミテッド Ｔｉｅ−２および／またはｖｅｇｆｒ−２の阻害剤として有用なベンゾイミダゾール誘導体
CZ20031751A3 (cs) 2000-12-21 2004-03-17 Glaxo Group Limited Makrolidy
KR100362390B1 (ko) 2000-12-29 2002-11-23 삼성전자 주식회사 화상형성장치의 현상기-토너 카트리지 조립체
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
JP2004532187A (ja) 2001-01-25 2004-10-21 ギルフォード ファーマシュウティカルズ インコーポレイテッド 三置換カルボサイクリックサイクロフィリン結合化合物とその用途
FR2820136A1 (fr) 2001-01-26 2002-08-02 Aventis Pharma Sa Nouveaux derives de l'uree, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
WO2002059081A2 (fr) 2001-01-26 2002-08-01 Kirin Beer Kabushiki Kaisha Derives d'uree en tant qu'inhibiteurs du recepteur ccr-3
US6670364B2 (en) 2001-01-31 2003-12-30 Telik, Inc. Antagonists of MCP-1 function and methods of use thereof
LT2762140T (lt) 2001-02-19 2017-06-26 Novartis Ag Solidinių smegenų navikų gydymas rapamicino dariniu
UA76977C2 (en) 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
WO2002076930A2 (fr) 2001-03-07 2002-10-03 Telik, Inc. Stimulateurs de l'apoptose à médiation des fas à base de diarylurées substituées
US6525091B2 (en) 2001-03-07 2003-02-25 Telik, Inc. Substituted diarylureas as stimulators for Fas-mediated apoptosis
MXPA03008659A (es) 2001-03-23 2005-04-08 Bayer Ag Inhibidores de rho-cinasa.
EP1381594A1 (fr) 2001-04-13 2004-01-21 Boehringer Ingelheim Pharmaceuticals Inc. Composes d'uree utilises en tant qu'agents anti-inflammatoires
WO2002083628A1 (fr) 2001-04-13 2002-10-24 Boehringer Ingelheim Pharmaceuticals, Inc. Composes benzo-fusionnes a disubstitution en positions 1,4
US7371763B2 (en) 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
US20030207914A1 (en) 2001-04-20 2003-11-06 Bayer Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
WO2002085857A2 (fr) 2001-04-20 2002-10-31 Bayer Corporation Inhibition de la kinase raf a l'aide d'urees de quinolyl, d'isoquinolyl ou de pyridyl
CA2445357A1 (fr) 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Inhibiteurs de kinases derives du pyrazole
JP2004530690A (ja) 2001-05-16 2004-10-07 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 抗炎症性薬剤として有用なジアリールウレア誘導体
ATE360417T1 (de) 2001-07-11 2007-05-15 Boehringer Ingelheim Pharma Methode zur behandlung von zytokinvermittelten erkrankungen
US7371736B2 (en) 2001-11-07 2008-05-13 The Board Of Trustees Of The University Of Arkansas Gene expression profiling based identification of DKK1 as a potential therapeutic targets for controlling bone loss
SE0103838D0 (sv) 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product
EP1769795B1 (fr) 2001-12-03 2013-07-24 Bayer HealthCare LLC Composés de type urée aryle combinés à d'autres agents cytostatiques ou cytotoxiques et servant a traiter des cancers humains
EP1578346A4 (fr) 2001-12-04 2007-11-28 Onyx Pharma Inc Inhibiteurs de la voie raf-mek-erk pour traiter le cancer
ES1050706Y (es) 2001-12-12 2002-08-16 Climastar Thermostone S L Convector electrico mejorado
WO2003056036A2 (fr) 2001-12-21 2003-07-10 The Wellcome Trust Genes
US20040096855A1 (en) 2001-12-24 2004-05-20 Michael Stratton Genes
AU2002356323A1 (en) 2001-12-24 2003-07-30 Catalyst Biomedica Limited Cancer-specific mutants of b-raf genes and uses thereof
US20080108672A1 (en) 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
US20030207872A1 (en) 2002-01-11 2003-11-06 Bayer Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2003059373A2 (fr) 2002-01-16 2003-07-24 Ramot At Tel Aviv University Ltd. Procedes et compositions destines a stimuler ou a inhiber la fecondation
EP1470121B1 (fr) 2002-01-23 2012-07-11 Bayer HealthCare LLC Derives pyrimidine en tant qu'inhibiteurs de kinase rho
ATE381557T1 (de) 2002-01-23 2008-01-15 Bayer Pharmaceuticals Corp Rho-kinase inhibitoren
US6998391B2 (en) 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
SI1478358T1 (sl) 2002-02-11 2013-09-30 Bayer Healthcare Llc Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
US7928277B1 (en) 2002-02-11 2011-04-19 Cox Jr Henry Wilmore Method for reducing contamination
US20030216396A1 (en) 2002-02-11 2003-11-20 Bayer Corporation Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
SI1580188T1 (sl) 2002-02-11 2012-02-29 Bayer Healthcare Llc Aril sečnine kot kinazni inhibitorji
US7645878B2 (en) 2002-03-22 2010-01-12 Bayer Healthcare Llc Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
US8299108B2 (en) 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
AR037647A1 (es) 2002-05-29 2004-12-01 Novartis Ag Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina
WO2004019941A1 (fr) 2002-08-27 2004-03-11 Merck Patent Gmbh Derives de la glycinamide, inhibiteurs de la raf-kinase
DE60328202D1 (de) 2002-09-05 2009-08-13 Neurosearch As Diarylharnstoffderivate und deren verwendung als chloridkanalblocker
RU2005115842A (ru) 2002-10-24 2006-03-10 Мерк Патент ГмбХ (DE) Производные метиленмочевины
ES2421516T3 (es) 2002-11-06 2013-09-03 Dana Farber Cancer Inst Inc Composiciones para tratar el cáncer usando el inhibidor de proteasomas PS-341
PL376169A1 (en) 2002-11-15 2005-12-27 Novartis Ag Drug delivery system
SE0203654D0 (sv) 2002-12-09 2002-12-09 Astrazeneca Ab New compounds
US20030232400A1 (en) 2002-12-20 2003-12-18 Susan Radka Methods of screening subjects for expression of soluble receptors of vascular endothelial growth factor (VEGF) for use in managing treatment and determining prognostic outcome
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
GB0317227D0 (en) 2003-07-23 2003-08-27 Pfizer Ltd Treatment of male sexual dysfunction
EP1603879A2 (fr) 2003-02-28 2005-12-14 Bayer Pharmaceuticals Corporation Derives de pyridine substitues utilises pour traiter des cancers et d'autres troubles
WO2004078746A2 (fr) 2003-02-28 2004-09-16 Bayer Pharmaceuticals Corporation Derives de 2-oxo-1,3,5-perhydrotriazapine destines au traitement de maladies hyperproliferatives, angiogeniques et inflammatoires
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
EP1608639A2 (fr) 2003-02-28 2005-12-28 Bayer Pharmaceuticals Corporation Nouveaux derives bicycliques d'uree utiles dans le traitement du cancer et d'autres troubles
US7531553B2 (en) 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
BRPI0407968A (pt) 2003-03-24 2006-03-07 Merck Patent Gmbh derivados de oxamida úteis como inibidores de raf-quinase
US6896863B2 (en) 2003-04-01 2005-05-24 E. I. Du Pont De Nemours And Company Sodium cyanide process
EP1626714B1 (fr) 2003-05-20 2007-07-04 Bayer Pharmaceuticals Corporation Urees de diaryle pour des maladies mediees par le recepteur du facteur de croissance derive des plaquettes
US20040259926A1 (en) 2003-06-05 2004-12-23 Bruendl Michelle M. 3-Aryloxy and 3-heteroaryloxy substituted benzo[b]thiophenes as therapeutic agents
EP1636210A1 (fr) 2003-06-05 2006-03-22 Warner-Lambert Company LLC Benzothiophenes substitutes par cycloalkyle et heterocycloalkyle, utiles comme agents therapeutiques
GB2403151A (en) 2003-06-27 2004-12-29 Intermark Medical Innovations A device for rectal lavage
WO2005002673A1 (fr) 2003-07-03 2005-01-13 Astex Therapeutics Limited Inhibiteurs de raf kinase
US20070213374A1 (en) 2003-07-07 2007-09-13 Merck Patent Gmbh Malonamide Derivatives
AU2004255340B2 (en) 2003-07-08 2008-05-01 Novartis Ag Use of rapamycin and rapamycin derivatives for the treatment of bone loss
EP1648900A4 (fr) 2003-07-11 2010-02-10 Ariad Pharma Inc Macrocycles contenant du phosphore
JP5001650B2 (ja) 2003-07-11 2012-08-15 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンズイミダゾールカルボキサミド
ES2380201T3 (es) 2003-07-11 2012-05-09 Merck Patent Gmbh Derivados de benzimidazol
WO2005009367A2 (fr) 2003-07-17 2005-02-03 Ambit Biosciences Corporation Traitement de maladies au moyen d'inhibiteurs de kinase
EP1663978B1 (fr) 2003-07-23 2007-11-28 Bayer Pharmaceuticals Corporation Omega-carboxyaryldiphenyluree fluoro-subtituee pour le traitement et la prevention de maladies et d'etats pathologiques
GB0317229D0 (en) 2003-07-23 2003-08-27 Pfizer Ltd Improved process
AR045134A1 (es) 2003-07-29 2005-10-19 Smithkline Beecham Plc Compuesto de 1h - imidazo [4,5-c] piridin-ilo, composicion farmaceutica que lo comprende, proceso para prepararla, su uso para preparar dicha composicion farmaceutica, combinacion farmaceutica, uso de la combinacion farmaceutica para la preparacion de un medicamento, procedimientos para preparar dic
DE10334663A1 (de) 2003-07-30 2005-03-10 Merck Patent Gmbh Harnstoffderivate
BRPI0414698A (pt) 2003-09-23 2006-11-28 Novartis Ag combinação de um inibidor receptor de vegf com um agente quimioterapêutico
DE10344223A1 (de) 2003-09-24 2005-04-21 Merck Patent Gmbh 1,3-Benzoxazolylderivate als Kinase-Inhibitoren
JP2007509846A (ja) 2003-10-15 2007-04-19 バイエル・ヘルスケア・アクチェンゲゼルシャフト テトラヒドロ−ナフタレンおよび尿素誘導体
US20050084835A1 (en) 2003-10-16 2005-04-21 The Singing Machine Company, Inc. Karaoke system with built-in camera
KR20060118472A (ko) 2003-10-16 2006-11-23 카이론 코포레이션 치환 벤자졸 및 ｒａｆ 키나아제의 저해제로서 그것의 사용
DE10349587A1 (de) 2003-10-24 2005-05-25 Merck Patent Gmbh Benzimidazolylderivate
DE10352979A1 (de) 2003-11-13 2005-06-09 Merck Patent Gmbh Pyridopyrimidinone
EP1684762A4 (fr) 2003-11-13 2009-06-17 Ambit Biosciences Corp Derives d'uree en tant que modulateurs de la kinase
DE10354060A1 (de) 2003-11-19 2005-06-02 Merck Patent Gmbh Pyrrolderivate
ATE447957T1 (de) 2003-12-09 2009-11-15 Us Gov Health & Human Serv Verfahren zur unterdrückung einer immunantwort oder zur behandlung von proliferativen erkrankungen
AU2004299174A1 (en) 2003-12-10 2005-06-30 Merck Patent Gmbh Diacylhydrazine derivatives
BRPI0507198A (pt) 2004-01-30 2007-06-26 Merck Patent Gmbh derivados de bisariluréia
CA2560269A1 (fr) 2004-03-19 2005-09-29 The Penn State Research Foundation Procedes et compositions combinatoires pour le traitement de melanome
WO2005110994A2 (fr) 2004-04-30 2005-11-24 Bayer Pharmaceuticals Corporation Derives de pyrazolyl uree substitues utiles dans le traitement du cancer
MY191349A (en) 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
CN101048140B (zh) 2004-08-27 2013-06-19 拜尔保健公司 用于治疗癌症的药物组合物
US7745446B2 (en) 2004-09-06 2010-06-29 Bayer Schering Pharma Aktiengesellschaft Pyrazolo[1,5-c]pyrimidines
BRPI0515946A (pt) 2004-09-29 2008-08-12 Bayer Healthcare Ag sal de tosilato, sua preparação e uso, bem como composição farmacêutica compreendendo o mesmo
KR101263032B1 (ko) 2004-09-29 2013-05-09 바이엘 파마 악티엔게젤샤프트 4-｛4-［（｛［4-클로로-3-（트리플루오로메틸）페닐］아미노｝카르보닐）아미노］페녹시｝-ｎ-메틸피리딘-2-카르복사미드의 제조 방법
PL1858877T3 (pl) 2005-01-14 2014-08-29 Gilead Connecticut Inc 1,3 podstawione diarylem moczniki jako modulatory aktywności kinazy
CA2601955C (fr) 2005-03-07 2012-07-10 Bayer Healthcare Ag Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancer
DE102005015253A1 (de) 2005-04-04 2006-10-05 Merck Patent Gmbh Pyrazolderivate
RU2007148266A (ru) 2005-05-27 2009-07-10 Байер ХельсКер АГ (DE) Комбинированная терапия с использованием соединения диарилмочевины и ингибиторов pi3, akt-киназы или mtor (рапамицины) для лечения рака
KR20080012902A (ko) 2005-05-27 2008-02-12 바이엘 헬스케어 아게 질병을 치료하기 위한 디아릴 우레아를 포함하는 병용요법
BRPI0617167B8 (pt) 2005-09-21 2021-05-25 Nycomed Gmbh sulfonilpirróis como inibidores de hdac's, seu uso, composição farmacêutica e combinação
RU2395090C2 (ru) 2005-10-21 2010-07-20 БАЙЕР ХелсКер ЛЛСи Способы прогнозирования и предсказания рака и мониторинг терапии раковых заболеваний
EP2289515A3 (fr) 2005-10-31 2012-04-11 Bayer HealthCare LLC Combinaison contenant une diaryl urée et un interferon
US8329408B2 (en) 2005-10-31 2012-12-11 Bayer Healthcare Llc Methods for prognosis and monitoring cancer therapy
WO2007053573A2 (fr) 2005-10-31 2007-05-10 Bayer Pharmaceuticals Corporation Traitement du cancer au moyen de sorafenib
US20080311601A1 (en) 2005-11-02 2008-12-18 Elting James J Methods for Prediction and Prognosis of Cancer, and Monitoring Cancer Therapy
EP1948176B1 (fr) 2005-11-10 2011-01-05 Bayer Schering Pharma Aktiengesellschaft Diaryle-urees permettant de traiter l'hypertension pulmonaire
AU2006312714A1 (en) 2005-11-10 2007-05-18 Bayer Schering Pharma Aktiengesellschaft Diaryl urea for treating pulmonary hypertension
CN101454668A (zh) 2005-11-14 2009-06-10 拜耳医药保健有限责任公司 癌症预测与预后以及监测癌症治疗的方法
WO2007059155A1 (fr) 2005-11-14 2007-05-24 Bayer Pharmaceuticals Corporation Traitement de cancers a resistance a des agents chimiotherapeutiques
US20100144749A1 (en) 2005-11-14 2010-06-10 Scott Wilhelm Treatment of cancers with acquired resistance to kit inhibitors
US20110195110A1 (en) 2005-12-01 2011-08-11 Roger Smith Urea compounds useful in the treatment of cancer
JP2009524585A (ja) 2005-12-15 2009-07-02 バイエル・ヘルスケア・アクチェンゲゼルシャフト ウイルス感染を処置するためのジアリールウレア
US20090227637A1 (en) 2005-12-15 2009-09-10 Olaf Weber Diaryl ureas for treating virus infections
US20100129321A1 (en) 2005-12-15 2010-05-27 Bayer Healthcare Llc Diaryl urea for treating virus infections
EP1973897B1 (fr) 2005-12-21 2014-05-21 Bayer Intellectual Property GmbH Dérivés substitués de la pyrimidine utilisables dans le traitement du cancer et d'autres maladies
WO2007087575A2 (fr) 2006-01-24 2007-08-02 University Of Chicago Compositions et procedes destines au traitement de l'hypertension pulmonaire
EP2002264A2 (fr) 2006-03-31 2008-12-17 Bayer HealthCare LLC Procedes de prevision et de pronostic de cancer, et surveillance d'une therapie anticancereuse
WO2007139930A2 (fr) 2006-05-26 2007-12-06 Bayer Healthcare Llc Associations de médicaments comportant des urées de diaryle substituées pour le traitement du cancer
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
EP2089003A1 (fr) 2006-11-09 2009-08-19 Abbott GmbH & Co. KG Forme de dosage pharmaceutique pour l'administration orale d'un inhibiteur de la tyrosine kinase
CA2668748A1 (fr) 2006-11-09 2008-05-15 Bayer Schering Pharma Aktiengesellschaft Polymorphe iii de 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide
EP2089363A1 (fr) 2006-11-14 2009-08-19 Bayer Schering Pharma Aktiengesellschaft Polymorphe ii de 4-[4-({[4-chloro-3-(trifluorométhyl)phényl]carbamoyl}amino)-3-fluorophénoxy]-n-méthylpyridine-2-carboxamide
JP2010514691A (ja) 2006-12-20 2010-05-06 バイエル ヘルスケア リミティド ライアビリティ カンパニー ４−｛４−〔（｛３−ｔｅｒｔ−ブチル−１−〔３−（ヒドロキシメチル）フェニル〕−１Ｈ−ピラゾール−５−イル｝カルバモイル）アミノ〕−３−フルオロフェノキシ｝−Ｎ−メチルピリジン−２−カルボキサミド並びに癌の治療のためのそれのプロドラッグ及び塩
WO2008079972A2 (fr) 2006-12-20 2008-07-03 Bayer Healthcare Llc Composé d'hydroxy méthyle phényle pyrazolyle urée utilisé pour traiter un cancer
WO2008089388A2 (fr) 2007-01-19 2008-07-24 Bayer Healthcare Llc Traitement de cancers présentant une résistance à des agents chimiothérapeutiques
US8680124B2 (en) 2007-01-19 2014-03-25 Bayer Healthcare Llc Treatment of cancers with acquired resistance to kit inhibitors
WO2008156024A1 (fr) 2007-06-21 2008-12-24 Sharp Kabushiki Kaisha Photodétecteur et dispositif d'affichage associé
JP5076072B2 (ja) 2008-03-24 2012-11-21 矢崎総業株式会社 圧着端子、及びこの圧着端子を用いた圧着構造
US20110178137A1 (en) 2008-06-25 2011-07-21 Bayer Schering Pharma Aktiengesellschaft Diaryl urea for treating heart failure
WO2010048304A2 (fr) 2008-10-21 2010-04-29 Bayer Healthcare Llc Identification de gènes signature associés à un carcinome hépatocellulaire
JP5077375B2 (ja) 2010-02-26 2012-11-21 井関農機株式会社 コンバイン

Also Published As

Publication number Publication date
AU2011201337B2 (en) 2013-02-14
AR079933A2 (es) 2012-02-29
CN1856469B (zh) 2013-03-06
AR091405A2 (es) 2015-02-04
CY2013039I2 (el) 2015-11-04
UA84156C2 (ru) 2008-09-25
HK1093978A1 (en) 2007-03-16
ES2297490T3 (es) 2008-05-01
AU2011201337A1 (en) 2011-04-14
RS52625B (sr) 2013-06-28
MY142799A (en) 2010-12-31
WO2005009961A2 (fr) 2005-02-03
LU92300I2 (fr) 2013-12-30
CR10193A (fr) 2008-09-30
CA2532865C (fr) 2013-08-06
IL173256A0 (en) 2006-06-11
US8637553B2 (en) 2014-01-28
BR122016015715B1 (pt) 2020-10-20
CL2004001834A1 (es) 2005-06-03
IL173256A (en) 2011-03-31
KR20060052866A (ko) 2006-05-19
BRPI0412219B1 (pt) 2018-02-06
AU2004259760A1 (en) 2005-02-03
ECSP066302A (es) 2006-07-28
DE602004010407T2 (de) 2008-10-16
TW200524604A (en) 2005-08-01
EP1663978A2 (fr) 2006-06-07
JP2006528196A (ja) 2006-12-14
FR13C0060I1 (fr) 2013-12-13
CN102816113B (zh) 2015-05-13
JP4777887B2 (ja) 2011-09-21
DK1663978T3 (da) 2008-04-07
WO2005009961B1 (fr) 2005-06-02
NO335323B1 (no) 2014-11-10
AU2004259760B2 (en) 2010-12-23
LU92300I9 (fr) 2019-01-16
CN1856469A (zh) 2006-11-01
JP5505906B2 (ja) 2014-05-28
DE602004010407D1 (de) 2008-01-10
EA200600317A1 (ru) 2006-06-30
EP1663978B1 (fr) 2007-11-28
BR122016015715B8 (pt) 2021-05-25
HRP20060073A2 (en) 2006-06-30
CY2013039I1 (el) 2015-11-04
BE2013C067I2 (fr) 2023-08-09
AR048741A1 (es) 2006-05-24
HUS1300073I1 (hu) 2017-04-28
JP2011168599A (ja) 2011-09-01
AU2004259760B9 (en) 2011-02-03
CY1107094T1 (el) 2012-10-24
CA2532865A1 (fr) 2005-02-03
RS20060037A (sr) 2008-06-05
TWI341201B (en) 2011-05-01
NO20060870L (no) 2006-04-07
HK1179259A1 (en) 2013-09-27
NZ544920A (en) 2009-11-27
SI1663978T1 (sl) 2008-02-29
EA010485B1 (ru) 2008-10-30
HRP20060073B1 (hr) 2014-03-14
KR101139557B1 (ko) 2012-04-30
MA27946A1 (fr) 2006-06-01
CN102816113A (zh) 2012-12-12
MEP38308A (en) 2011-02-10
US20130131122A1 (en) 2013-05-23
PL1663978T3 (pl) 2008-04-30
NZ580384A (en) 2011-03-31
TNSN06020A1 (en) 2007-10-03
US20090192127A1 (en) 2009-07-30
BRPI0412219B8 (pt) 2021-07-27
PT1663978E (pt) 2008-02-15
BRPI0412219A (pt) 2006-08-22
US20050038080A1 (en) 2005-02-17
ME00294B (fr) 2011-05-10
WO2005009961A3 (fr) 2005-03-31

Similar Documents

Publication Publication Date Title
FR13C0060I2 (fr) Omega-carboxyaryldiphenyluree fluoro-subtituee pour le traitement et la prevention de maladies et d'etats pathologiques
EP1604664A4 (fr) Medicament pour la prevention et le traitement de l'arteriosclerose et de l'hypertension
ATE396202T1 (de) Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen
DZ3500A1 (fr) Derives de phenethanolamine pour le traitement de maladies respiratoires
EP1438062A4 (fr) Methodes et compositions pour le traitement de lesions cutanees
EP1534074A4 (fr) Polytherapie pour le traitement de l'obesite
EP1489915A4 (fr) Traitement et prevention de troubles inflammatoires
FR2854074B1 (fr) Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
CH1143977H1 (fr) 2-Oxy-benzoxazine-4-ones destinees au traitement de l'obesite
PT1446122E (pt) Utilizacao de flibanserina no tratamento de disturbios de desejo sexual
EP1711197A4 (fr) Methodes et compositions pour la prevention et le traitement de maladies ou de troubles inflammatoires
EP1311261A4 (fr) Medicaments pour le traitement chimiotherapeutique de maladies
MA27027A1 (fr) Inhibiteur de pde4 et agent anticholinergique en association pour le traitement de maladies obstructives des voies aeriennes
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
MA28806B1 (fr) Derives d'arylsulfonylstilbene destines au traitement de l'insomnie et de conditions apparentees
FR13C0044I2 (fr) Utilisation de dihydroimidazolones pour le traitement de l'epilepsie canine
EP1830873A4 (fr) Glyponectine (adiponectine glycosylee) pour le traitement de maladies et d'etats pathologiques
PL371281A1 (en) Methods and compositions for the treatment of eye diseases
EP1469852A4 (fr) Donneurs de monoxyde d'azote pour le traitement de maladies et de blessures
EP1448193A4 (fr) Composes therapeutiques pour le traitement d'etats dyslipidemiques
FR2828647B1 (fr) Maquillage-soin de la peau pour le traitement et la prevention du vieillissement
EP1547594A4 (fr) Prevention ou traitement d'escarres de decubitus
DZ3225A1 (fr) Methode et compositions pour le traitement des maladies pulmonaires
EP1572129A4 (fr) Derives d'amidine pour le traitement des amyloses